187 related articles for article (PubMed ID: 26426637)
1. Predictive Value of Ercc1 and Xpd Polymorphisms for Clinical Outcomes of Patients Receiving Neoadjuvant Therapy: A Prisma-Compliant Meta-Analysis.
Qixing M; Gaochao D; Wenjie X; Rong Y; Feng J; Lin X; Mantang Q; Qiang C
Medicine (Baltimore); 2015 Sep; 94(39):e1593. PubMed ID: 26426637
[TBL] [Abstract][Full Text] [Related]
2. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
Rumiato E; Cavallin F; Boldrin E; Cagol M; Alfieri R; Basso D; Castoro C; Ancona E; Amadori A; Ruol A; Saggioro D
Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907
[TBL] [Abstract][Full Text] [Related]
3. ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.
Lu X; Xiao S; Jin C; van der Straaten T; Li X
J Clin Lab Anal; 2012 Jan; 26(1):10-5. PubMed ID: 24833529
[TBL] [Abstract][Full Text] [Related]
4. Association between common polymorphisms in ERCC gene and glioma risk: A meta-analysis of 15 studies.
Qian T; Zhang B; Qian C; He Y; Li Y
Medicine (Baltimore); 2017 May; 96(20):e6832. PubMed ID: 28514298
[TBL] [Abstract][Full Text] [Related]
5. Genotypes and haplotypes of ERCC1 and ERCC2/XPD genes predict levels of benzo[a]pyrene diol epoxide-induced DNA adducts in cultured primary lymphocytes from healthy individuals: a genotype-phenotype correlation analysis.
Zhao H; Wang LE; Li D; Chamberlain RM; Sturgis EM; Wei Q
Carcinogenesis; 2008 Aug; 29(8):1560-6. PubMed ID: 18635523
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in ERCC1 and ERCC2/XPD genes and carcinogen DNA adducts in human lung.
Lee MS; Liu CY; Su L; Christiani DC
Lung Cancer; 2015 Jul; 89(1):8-12. PubMed ID: 26001533
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis.
Zhang H; Ge J; Hong H; Bi L; Sun Z
World J Surg Oncol; 2017 Apr; 15(1):75. PubMed ID: 28388903
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis.
Metzger R; Warnecke-Eberz U; Alakus H; Kütting F; Brabender J; Vallböhmer D; Grimminger PP; Mönig SP; Drebber U; Hölscher AH; Bollschweiler E
J Gastrointest Surg; 2012 Jan; 16(1):26-34; discussion 34. PubMed ID: 21956434
[TBL] [Abstract][Full Text] [Related]
9. Roles of XRCC1/XPD/ERCC1 Polymorphisms in Predicting Prognosis of Hepatocellular Carcinoma in Patients Receiving Transcatheter Arterial Chemoembolization.
Wang XC; Wang F; Quan QQ
Genet Test Mol Biomarkers; 2016 Apr; 20(4):176-84. PubMed ID: 26918371
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
Mo J; Luo M; Cui J; Zhou S
Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
[TBL] [Abstract][Full Text] [Related]
11. A Comprehensive Analysis of Influence ERCC Polymorphisms Confer on the Development of Brain Tumors.
Geng P; Ou J; Li J; Liao Y; Wang N; Xie G; Sa R; Liu C; Xiang L; Liang H
Mol Neurobiol; 2016 May; 53(4):2705-14. PubMed ID: 26264164
[TBL] [Abstract][Full Text] [Related]
12. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
[TBL] [Abstract][Full Text] [Related]
13. ERCC1 and ERCC2 haplotype modulates induced BPDE-DNA adducts in primary cultured lymphocytes.
Lu X; Liu Y; Yu T; Xiao S; Bao X; Pan L; Zhu G; Cai Y; Liu Q; Jin C; Yang J; Wu S; An L; van der Straaten T
PLoS One; 2013; 8(4):e60006. PubMed ID: 23593158
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes.
Bradbury PA; Kulke MH; Heist RS; Zhou W; Ma C; Xu W; Marshall AL; Zhai R; Hooshmand SM; Asomaning K; Su L; Shepherd FA; Lynch TJ; Wain JC; Christiani DC; Liu G
Pharmacogenet Genomics; 2009 Aug; 19(8):613-25. PubMed ID: 19620936
[TBL] [Abstract][Full Text] [Related]
15. Association of genetic polymorphisms in ERCC1 and ERCC2/XPD with risk of chronic benzene poisoning in a Chinese occupational population.
Xiao S; Gao L; Liu Y; Yu T; Jin C; Pan L; Zhu G; Lu X
Mutat Res; 2013 Feb; 751(1):52-8. PubMed ID: 23147699
[TBL] [Abstract][Full Text] [Related]
16. Systematic review on the association between ERCC1 rs3212986 and ERCC2 rs13181 polymorphisms and glioma risk.
Zhou CX; Zhao JH
Genet Mol Res; 2015 Mar; 14(1):2868-75. PubMed ID: 25867436
[TBL] [Abstract][Full Text] [Related]
17. Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma.
Cao ZH; Yin HP; Jiang N; Yu B
Genet Mol Res; 2015 Aug; 14(3):10145-51. PubMed ID: 26345951
[TBL] [Abstract][Full Text] [Related]
18. Variants in nucleotide excision repair core genes and susceptibility to recurrence of squamous cell carcinoma of the oropharynx.
Song X; Sturgis EM; Jin L; Wang Z; Wei Q; Li G
Int J Cancer; 2013 Aug; 133(3):695-704. PubMed ID: 23335232
[TBL] [Abstract][Full Text] [Related]
19. Association Between
Boldrin E; Malacrida S; Rumiato E; Battaglia G; Ruol A; Amadori A; Saggioro D
Front Oncol; 2019; 9():85. PubMed ID: 30847299
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis.
Wei SZ; Zhan P; Shi MQ; Shi Y; Qian Q; Yu LK; Song Y
Med Oncol; 2011 Mar; 28(1):315-21. PubMed ID: 20143185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
